EP
AKBA icon

Essential Partners’s Akebia Therapeutics AKBA Stock Holding History

Essential Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.82K Buy
3,350
+2,736
+446% +$3.26K ﹤0.01% 1665
2026
Q1 		$853 Buy
+614
New +$844 ﹤0.01% 2288
2025
Q4 		– Sell
-550
Closed -$1.5K – 2776
2025
Q3 		$1.5K Buy
550
+13
+2% +$43 ﹤0.01% 1889
2025
Q2 		$1.96K Buy
+537
New +$1.48K ﹤0.01% 1323

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Essential Partners's AKBA Position: Q2 2026 in Review

Essential Partners increased its Akebia Therapeutics (AKBA) stake by 446% in Q2 2026, buying an estimated $3.26K and bringing the position to 3,350 shares worth $3.82K. The position accounts for ﹤0.01% of the portfolio, ranked #1665.

Essential Partners first reported a position in AKBA in Q2 2025 and has held it in 4 quarters since. 170 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Essential Partners held 3,350 shares of Akebia Therapeutics worth $3.82K as of Q2 2026.
  • Essential Partners bought 2,736 Akebia Therapeutics shares in Q2 2026, an estimated $3.26K.
  • Akebia Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1665 holding.
  • Essential Partners first reported a position in Akebia Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 170 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.